3,8-dichloro-dibenzo[b,f][1,4]oxazepin-11(10H)-one | 908336-78-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3,8-dichloro-dibenzo[b,f][1,4]oxazepin-11(10H)-one
• 英文别名: 3,8-dichlorodibenzo[b,f][1,4]oxazepin-11(10H)-one；3,8-dichloro-10H-dibenzo[b,f][1,4]oxazepin-11-one；3,9-dichloro-5H-benzo[b][1,4]benzoxazepin-6-one
• CAS: 908336-78-7
• 化学式: C₁₃H₇Cl₂NO₂
• 分子量: 280.11
• InChiKey: MDZJVBOKIOULBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,8-dichloro-dibenzo[b,f][1,4]oxazepin-11(10H)-one 在 三氯氧磷 作用下， 生成
  参考文献：
  名称：

  二苯并[b，f] [1,4]氮杂ze庚因和二苯并[b，e] Oxepinesine：在H1R，H4R，5-HT2AR和其他选定的GPCR中，氯取代方式对药理学的影响。

  摘要：

  受到VUF6884（7-Chloro-11-（4-methylpiperazin-1-yl）dibenzo [b，f] [1,4] oxazep​​ine的启发），报道为双重H1 / H4受体配体（pKi：8.11（人H1R（ hH1R）），7.55（人H4R（hH4R））），四种已知的和28种新的奥氮平及其相关的奥西平衍生物已合成，并在组胺受体和选定的胺能GPCR上进行了药理学表征。与奥氮平系列相反，在奥西平系列中，新化合物显示出对hH1R的高亲和力（pKi：6.8-8.7），但对hH4R的亲和力不高（pKi：≤5.3）。对于一种oxepine衍生物（1-（2-氯-6,11-二氢二苯并[b，e] oxepin-11-基] -4-甲基哌嗪），对映体被分离，R-对映体被鉴定为是对映体。 hH1R（pKi：8.83（R），7.63（S））和豚鼠H1R（gpH1R）（pKi：8.82（R），7.

  DOI：

  10.1016/j.phrs.2016.09.042
• 作为产物：
  描述：

  2,4-二氯苯甲酸 在 sodium hydroxide 、 氯化亚砜 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 3,8-dichloro-dibenzo[b,f][1,4]oxazepin-11(10H)-one
  参考文献：
  名称：

  Characterization of the Histamine H₄ Receptor Binding Site. Part 1. Synthesis and Pharmacological Evaluation of Dibenzodiazepine Derivatives

  摘要：

  A series of dibenzodiazepine derivatives was synthesized to probe the binding site of the recently discovered histamine H-4 receptor (H4R). Optimization of the lead structure clozapine (2) resulted in (E)-7-chloro-11-(4-methylpiperazin-l-yl) dibenzo[b, f][1,4] oxazepine (7j), a potent H4R agonist (H4R, pK(i) = 7.6). Pharmacological data suggests that the series of nonimidazole compounds can be used to describe the orthosteric binding site of the H4R because both 2 and 7j displace [H-3] histamine in a competitive manner. Furthermore, it is demonstrated that the effects of 7j are competitively antagonized by the selective H4R antagonist JNJ 7777120 (1), indicating considerable overlap of their binding sites. On the basis of the derived structure-activity relationships and additional pharmacological results, a pharmacophore model was constructed, which will be the premise for the design of novel H4R ligands.

  DOI：

  10.1021/jm051008s

文献信息

• A highly-efficient palladium-catalyzed aminocarbonylation/S_NAr approach to dibenzoxazepinones
  作者：Chaoren Shen、Helfried Neumann、Xiao-Feng Wu

  DOI：10.1039/c5gc00427f

  日期：——

  A practical protocol for the synthesis of dibenzo[b,e][1,4]oxazepin-11(5H)-ones has been developed. By virtue of Pd-catalyzed aminocarbonylation and aromatic nucleophilic substitution, 61 examples of the desired dibenzoxazepinones were obtained in moderate to excellent isolated yields (54-92%).

  已经开发了一种实用的合成二苯并[b，e] [1,4]草酰pin11（5H）-ones的协议。借助于Pd催化的氨基羰基化和芳族亲核取代，以中等至优异的分离产率（54-92％）获得了61个所需的二苯并恶嗪酮类实例。
• Dibenzo[ b , f ][1,4]oxazepines and dibenzo[ b , e ]oxepines: Influence of the chlorine substitution pattern on the pharmacology at the H 1 R, H 4 R, 5-HT 2A R and other selected GPCRs
  作者：Franziska Naporra、Susanne Gobleder、Hans-Joachim Wittmann、Julia Spindler、Michael Bodensteiner、Günther Bernhardt、Harald Hübner、Peter Gmeiner、Sigurd Elz、Andrea Strasser

  DOI：10.1016/j.phrs.2016.09.042

  日期：2016.11

  lpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine), reported as a dual H1/H4 receptor ligand (pKi: 8.11 (human H1R (hH1R)), 7.55 (human H4R (hH4R))), four known and 28 new oxazepine and related oxepine derivatives were synthesised and pharmacologically characterized at histamine receptors and selected aminergic GPCRs. In contrast to the oxazepine series, within the oxepine series, the new compounds showed

  受到VUF6884（7-Chloro-11-（4-methylpiperazin-1-yl）dibenzo [b，f] [1,4] oxazep​​ine的启发），报道为双重H1 / H4受体配体（pKi：8.11（人H1R（ hH1R）），7.55（人H4R（hH4R））），四种已知的和28种新的奥氮平及其相关的奥西平衍生物已合成，并在组胺受体和选定的胺能GPCR上进行了药理学表征。与奥氮平系列相反，在奥西平系列中，新化合物显示出对hH1R的高亲和力（pKi：6.8-8.7），但对hH4R的亲和力不高（pKi：≤5.3）。对于一种oxepine衍生物（1-（2-氯-6,11-二氢二苯并[b，e] oxepin-11-基] -4-甲基哌嗪），对映体被分离，R-对映体被鉴定为是对映体。 hH1R（pKi：8.83（R），7.63（S））和豚鼠H1R（gpH1R）（pKi：8.82（R），7.
• Characterization of the Histamine H₄ Receptor Binding Site. Part 1. Synthesis and Pharmacological Evaluation of Dibenzodiazepine Derivatives
  作者：Rogier A. Smits、Herman D. Lim、Bart Stegink、Remko A. Bakker、Iwan J. P. de Esch、Rob Leurs

  DOI：10.1021/jm051008s

  日期：2006.7.1

  A series of dibenzodiazepine derivatives was synthesized to probe the binding site of the recently discovered histamine H-4 receptor (H4R). Optimization of the lead structure clozapine (2) resulted in (E)-7-chloro-11-(4-methylpiperazin-l-yl) dibenzo[b, f][1,4] oxazepine (7j), a potent H4R agonist (H4R, pK(i) = 7.6). Pharmacological data suggests that the series of nonimidazole compounds can be used to describe the orthosteric binding site of the H4R because both 2 and 7j displace [H-3] histamine in a competitive manner. Furthermore, it is demonstrated that the effects of 7j are competitively antagonized by the selective H4R antagonist JNJ 7777120 (1), indicating considerable overlap of their binding sites. On the basis of the derived structure-activity relationships and additional pharmacological results, a pharmacophore model was constructed, which will be the premise for the design of novel H4R ligands.